CRL — Charles River Laboratories International Share Price
Last trade - 00:00- $5.63bn
- $7.73bn
- $4.05bn
- 91
- 62
- 40
- 69
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 11.99 | ||
| PEG Ratio (f) | 0.31 | ||
| EPS Growth (f) | 61.53% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.63 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | 11.23 | ||
| Price to Sales | 1.39 | ||
| EV to EBITDA | 13.12 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 3.48% | ||
| Return on Equity | 0.3% | ||
| Operating Margin | 5.61% | ||
Financial Summary
| Year End 28th Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 2,923.93 | 3,540.16 | 3,976.06 | 4,129.41 | 4,049.99 | 3,820.74 | 3,945.77 | 9.09% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +33.54 | +4.58 | +16.62 | -14.9 | -46.05 | +118.2 | +7.84 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Charles River Laboratories International, Inc. is a drug development company. It provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions around the globe accelerate their research and drug development efforts. Its Research Models and Services segment includes three businesses that provide foundational tools that enable its clients to discover new molecules: Research Models, Research Model Services, and Cell Solutions. Its Discovery and Safety Assessment segment provides regulated and non-regulated DSA services to support the research, development, and regulatory-required safety testing of potential new drugs, including therapeutic discovery and optimization plus in vitro and in vivo studies, laboratory support services, and strategic non-clinical consulting and program management to support product development. Its Manufacturing Solutions segment includes Microbial Solutions and Biologics Solutions.
Directors
- James Foster CHM (70)
- David Smith CFO
- Birgit Girshick COO (51)
- William Barbo EVP (60)
- Joseph LaPlume EVP (47)
- George Milne LED (77)
- Nancy Andrews IND (64)
- Robert Bertolini IND (59)
- Deborah Kochevar IND (64)
- George Llado IND (55)
- Martin Mackay IND (65)
- George Massaro IND (73)
- Richard Reese IND (75)
- Richard Wallman IND (70)
- Virginia Wilson IND (66)
- Last Annual
- December 28th, 2024
- Last Interim
- December 28th, 2024
- Incorporated
- February 3rd, 1994
- Public Since
- June 23rd, 2000
- No. of Shareholders
- 63
- No. of Employees
- 18,600
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- New York Stock Exchange
- Shares in Issue
- 49,115,712
- Address
- 251 Ballardvale St, WILMINGTON, 01887
- Web
- https://www.criver.com/
- Phone
- +1 7812226000
- Auditors
- PricewaterhouseCoopers LLP
Latest News for CRL
Upcoming Events for CRL
Q1 2025 Charles River Laboratories International Inc Earnings Release
Q1 2025 Charles River Laboratories International Inc Earnings Call
Charles River Laboratories International Inc Annual Shareholders Meeting
Charles River Laboratories International Inc Annual Shareholders Meeting
Q2 2025 Charles River Laboratories International Inc Earnings Release
Similar to CRL
ADC Therapeutics SA
New York Stock Exchange
Alto Neuroscience
New York Stock Exchange
Annovis Bio
New York Stock Exchange
Arcus Biosciences
New York Stock Exchange
Aurion Biotech
New York Stock Exchange
FAQ
As of Today at 19:56 UTC, shares in Charles River Laboratories International are trading at $114.66. This share price information is delayed by 15 minutes.
Shares in Charles River Laboratories International last closed at $114.66 and the price had moved by -49.67% over the past 365 days. In terms of relative price strength the Charles River Laboratories International share price has underperformed the S&P500 Index by -53.54% over the past year.
The overall consensus recommendation for Charles River Laboratories International is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreCharles River Laboratories International does not currently pay a dividend.
Charles River Laboratories International does not currently pay a dividend.
Charles River Laboratories International does not currently pay a dividend.
To buy shares in Charles River Laboratories International you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $114.66, shares in Charles River Laboratories International had a market capitalisation of $5.63bn.
Here are the trading details for Charles River Laboratories International:
- Country of listing: United States
- Exchange: NYQ
- Ticker Symbol: CRL
Based on an overall assessment of its quality, value and momentum Charles River Laboratories International is currently classified as a Contrarian. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Charles River Laboratories International is $147.67. That is 28.79% above the last closing price of $114.66.
Analysts covering Charles River Laboratories International currently have a consensus Earnings Per Share (EPS) forecast of $9.32 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Charles River Laboratories International. Over the past six months, its share price has underperformed the S&P500 Index by -33.64%.
As of the last closing price of $114.66, shares in Charles River Laboratories International were trading -37.38% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Charles River Laboratories International PE ratio based on its reported earnings over the past 12 months is 11.99. The shares last closed at $114.66.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Charles River Laboratories International's management team is headed by:
- James Foster - CHM
- David Smith - CFO
- Birgit Girshick - COO
- William Barbo - EVP
- Joseph LaPlume - EVP
- George Milne - LED
- Nancy Andrews - IND
- Robert Bertolini - IND
- Deborah Kochevar - IND
- George Llado - IND
- Martin Mackay - IND
- George Massaro - IND
- Richard Reese - IND
- Richard Wallman - IND
- Virginia Wilson - IND